Reach Us +44-1647-403003
SNS01- An EIF5A-based Biologic With Significant Anti-tumoral Activity Following Systemic Administration In A Murine Model Of Multiple Myeloma | 1223
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

SNS01- An eIF5A-based biologic with significant anti-tumoral activity following systemic administration in a murine model of multiple myeloma

International Conference & Exhibition on Cancer Science & Therapy

John E. Thompson, Catherine Taylor and Richard Dondero

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956.S1.02

Eukaryotic translation initiation factor 5A (eIF5A) is post-translationally modified to hypusine-eIF5A and is the only known protein to contain hypusine. Recent studies have indicated that unhypusinated eIF5A is strongly pro-apoptotic, initiating both mitochondrial and death receptor mediated apoptosis, whereas hypusine-modified eIF5A has a pro-survival function SNS01 has two therapeutic components: (1) an RNAi-resistant plasmid with a B-cell-specific (B29) promoter encoding eIF5A K50R , a mutant of eIF5A that cannot be hypusinated; and (2) an siRNA that selectively suppresses endogenous hypusinated eIF5A which promotes growth of cancer cells. SNS01 nanoparticles are formed by complexing these therapeutic nucleic acids with polyethylenimine (PEI), a synthetic cationic polymer that serves as a delivery vehicle. SNS01 induces apoptosis in both IL- 6-responsive (KAS-6/1) and IL-6-independent (U266) myeloma cell lines and exhibits anti-tumoral activity when administered systemically to SCID mice bearing subcutaneous human multiple myeloma (KAS-6/1) tumors. Control mice treated with PEI nanoparticles containing a non-expressing plasmid and a non-targeting siRNA had an average tumour volume of 284 mm 3 at the time of sacrifice, whereas mice treated with 1.5 mg/kg or 0.75 mg/kg SNS01 exhibited significant tumor regression and had average tumor volumes of 13 mm 3 (95 % inhibition; *p = 0.026) and 24.5 mm 3 (91 % inhibition; *p = 0.03), respectively. TUNEL- labeling of tumor tissue indicated that tumor regression induced by SNS01 is attributable to apoptosis. Bio-distribution studies have indicated that that SNS01 nanoparticles are also taken up by B cells in the bone marrow. Thus SNS01 may be an effective treatment option for multiple myeloma patients.
John Thompson is Professor of Biology and Associate Vice-president, Research at the University of Waterloo, Chief Scientific Officer for Senesco Technologies Inc and a Fellow of the Royal Society of Canada. Catherine Taylor is a Senior Research Associate in John Thompson?s laboratory. Richard Dondero is Vice-president, Research and Development at Senesco Technologies Inc.
Relevant Topics